Running in Place: The 20th Anniversary of the NCCN Small Cell Lung Cancer Guidelines Panel

Restricted access

Gregory P. Kalemkerian, MD, is Professor in the Division of Hematology/Oncology at University of Michigan Medical School and Co-Director of the Thoracic Oncology Program at University of Michigan Comprehensive Cancer Center. He has been a member of the NCCN Small Cell Lung Cancer Panel since 1999 and the Panel Chair since 2006.

Dr. Kalemkerian earned his medical degree from Northwestern University Medical School in 1985, and completed his residency in internal medicine at Northwestern Memorial Hospital and a fellowship in medical oncology at the Johns Hopkins Oncology Center. From 1993 to 1999, he was a physician-scientist at Karmanos Cancer Institute in Detroit.

His clinical interests include the care of people with lung cancer, thymoma, and mesothelioma, and his research interest is experimental therapeutics for thoracic malignancies.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1.

    Demetri G, Elias A, Gershenson D. NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer. Oncology 1996;10:179194.

  • 2.

    Auperin A, Arriagada R, Pignon JP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476484.

    • Search Google Scholar
    • Export Citation
  • 3.

    O'Brien ME, Ciuleanu TE, Tsekov H. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:54415447.

    • Search Google Scholar
    • Export Citation
  • 4.

    Pignon JP, Arriagada R, Ihde DC. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:16181624.

  • 5.

    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890895.

    • Search Google Scholar
    • Export Citation
  • 6.

    Turrisi AT, Kim K, Blum R. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265271.

    • Search Google Scholar
    • Export Citation
  • 7.

    Slotman B, Faivre-Finn C, Kramer G. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664672.

  • 8.

    Seto T, Takahashi T, Yamanaka T. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): results of a Japanese randomized phase III trial [abstract]. J Clin Oncol 2014;32(Suppl 15):477s.

    • Search Google Scholar
    • Export Citation
  • 9.

    Slotman BJ, van Tinteren H, Praag JO. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015;385:3642.

    • Search Google Scholar
    • Export Citation
  • 10.

    Peifer M, Fernandez-Cuesta L, Sos ML. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genet 2012;44:11041110.

    • Search Google Scholar
    • Export Citation
  • 11.

    Rudin CM, Durnick S, Stawiski EW. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genet 2012;44:11111116.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 75 70 1
PDF Downloads 13 13 1
EPUB Downloads 0 0 0